Background: Direct oral anticoagulants (DOACs) have been found to be similar or superior
to warfarin in reducing ischemic stroke and intracranial hemorrhage (ICH) in patients with …

Four direct‐acting oral anticoagulants (DOACs)–the thrombin inhibitor dabigatran, and the
activated factor X (FXa) inhibitors apixaban, edoxaban, and rivaroxaban–are approved in …

Background The effects of anticoagulants at extremes of body weight (BW) are not well
described. The aim of this study was to analyze the pharmacokinetics/pharmacodynamics …

Background: Many publications have compared various outcomes defining safety and
efficacy of DOACs across different BMI ranges. Our meta-analysis compares warfarin and …

Direct acting non-Vitamin K antagonist oral anticoagulants (NOAC) are characterized by a
fixed dosing regimen. Despite the potential for relative underdosing due to large distribution …

Abstract Purpose Direct oral anticoagulants (DOACs) are recommended in preference to
vitamin K antagonists (VKAs) for stroke prevention in patients with atrial fibrillation (AF) …

Atrial fibrillation (AF) is associated with high risk of systemic thromboembolism leading to
significant morbidity and mortality. Warfarin, previously the mainstay for stroke prevention in …

Background: Elderly patients are at high risk of both ischaemic and bleeding events, and the
low body weight is considered a risk factor for major bleeding in atrial fibrillation (AF) …

Abstract Introduction Direct oral anticoagulants (DOACs) are widely employed for
antithrombotic prophylaxis in patients with atrial fibrillation (AF). However, there is still …

Background: In patients with venous thromboembolism (VTE), warfarin had been considered
standard of care until the new direct oral anticoagulants (DOACs) were developed. Studies …